Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Accelerator Invests in Four New Startups

NEW YORK (GenomeWeb) – Illumina has added four genomics startups to its accelerator program, marking its ninth funding round, the company said on Tuesday.

The startups are BioAmp Diagnostics, a precision diagnostics company based in Berkeley, California and focused on antibiotic resistance; Celldom, a North Carolina firm developing single-cell analysis technology; Juno Bio, which is based in the UK and developing vaginal microbiome technology for health and fertility; and TriAxia Health, which is based in Boston and developing a digital health platform to manage patients with rare disease.

As part of Illumina's six-month investment program, the companies have lab and office space at Illumina's San Francisco Bay Area facility, genomics and sequencing expertise, business coaching, and access to capital.

Illumina launched its accelerator program in 2014 and has so far invested in 34 companies.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.